SCHEMBL6267035

SCHEMBL6267035

NC(=O)COc1ccc2c(c1)S(=O)(=O)N=C(c1c(O)c3cc(OCC(N)=O)ccc3n(CCC3CC3)c1=O)N2

nearest known ligand 0.90

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.90
NR1I2 O75469 1/20 0.63
HSD17B10 Q99714 2/20 0.41
MAPK1 P28482 1/20 0.41
HIF1A Q16665 1/20 0.34
GRK2 P25098 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ADORA2A P29274 1/20 0.32
ADORA2B P29275 1/20 0.32
ADORA1 P30542 1/20 0.32
MGAT2 Q10469 2/20 0.31
DPP4 P27487 4/20 0.31
ALOX5AP P20292 1/20 0.30
CNR2 P34972 1/20 0.30
PLK1 P53350 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6234512 0.95 CYP2C9 (1.00) CYP2C9NR1I2HSD17B10MAPK1HIF1A
SCHEMBL6736116 0.95 CYP2C9 (0.84) CYP2C9NR1I2HSD17B10MAPK1HIF1A
SCHEMBL6684550 0.94 CYP2C9 (0.82) CYP2C9NR1I2HSD17B10MAPK1HIF1A
SCHEMBL6688874 0.88 CYP2C9 (0.88) CYP2C9NR1I2HSD17B10MAPK1HIF1A
SCHEMBL6232681 0.88 CYP2C9 (0.88) CYP2C9NR1I2HSD17B10MAPK1HIF1A
SCHEMBL7075766 0.88 CYP2C9 (0.73) CYP2C9NR1I2HSD17B10MAPK1HIF1A
SCHEMBL6231859 0.87 CYP2C9 (0.69) CYP2C9NR1I2HSD17B10MAPK1GRK2
SCHEMBL6732550 0.85 CYP2C9 (0.83) CYP2C9NR1I2HSD17B10MAPK1HIF1A
SCHEMBL6285555 0.85 CYP2C9 (0.83) CYP2C9NR1I2HSD17B10MAPK1HIF1A
SCHEMBL6235993 0.85 CYP2C9 (0.82) CYP2C9NR1I2HSD17B10MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401443-A4 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORP (US) 2005-10-26 EP claimed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US claimed
EP-1401443-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-03-31 EP claimed
WO-2002098424-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2002-12-12 WO claimed
EP-1401443-A4 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORP (US) 2005-10-26 EP disclosed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US disclosed
EP-1401443-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-03-31 EP disclosed
WO-2002098424-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147739-A1 Novel anti-infectives RPL5, RPL7, RPL35 CYP2C9 1218/4885NR1I2 1798/4885HSD17B10 1428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.